In this article, we will discuss Golimumab and Geriatric Use. So, let’s get started.
Golimumab and Geriatric Use
In the Phase 3 trials in RA, PsA, and AS, there were no overall differences in SAEs, serious infections, and AEs in Golimumab-treated patients ages 65 or older(N = 155) compared with younger SIMP aNI-treated patients. Because there is a higher incidence of infections in the geriatric population in general, caution should be used.in treating geriatric patients with Golimumab.